Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

Irinotecan/naxitamab/temozolomide

Anaphylaxis following compassionate use: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Munoz JP, et al. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes. Cancers 15: No. 19, Oct 2023. Available from: URL: https://www.mdpi.com/2072-6694/15/19/4837 Munoz JP, et al. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes. Cancers 15: No. 19, Oct 2023. Available from: URL: https://​www.​mdpi.​com/​2072-6694/​15/​19/​4837
Metadaten
Titel
Irinotecan/naxitamab/temozolomide
Anaphylaxis following compassionate use: case report
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-49158-1

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Celecoxib

Case report

Linezolid